The data here suggest that in addition to being mutated in cancers, KRAS is also amplified in ovarian, gastric, lung adenocarcinoma, and uterine cancers, with a copy number range 10–40 in ovarian cancers. Here, KRAS is linked to lung adenocarcinoma.